Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
18.22
+0.10 (0.55%)
At close: Oct 24, 2025, 4:00 PM EDT
17.95
-0.27 (-1.48%)
After-hours: Oct 24, 2025, 7:11 PM EDT
Roivant Sciences Revenue
Roivant Sciences had revenue of $2.17M in the quarter ending June 30, 2025, a decrease of -72.84%. This brings the company's revenue in the last twelve months to $23.23M, down -35.86% year-over-year. In the fiscal year ending March 31, 2025, Roivant Sciences had annual revenue of $29.05M, down -11.19%.
Revenue (ttm)
$23.23M
Revenue Growth
-35.86%
P/S Ratio
541.82
Revenue / Employee
$30,977
Employees
750
Market Cap
12.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 29.05M | -3.66M | -11.19% |
| Mar 31, 2024 | 32.71M | 1.18M | 3.75% |
| Mar 31, 2023 | 31.53M | -23.76M | -42.97% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ROIV News
- 4 weeks ago - Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Roivant Sciences Ltd. - Special Call - Seeking Alpha
- 5 weeks ago - Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial - Benzinga
- 5 weeks ago - Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial - Reuters
- 5 weeks ago - Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) - GlobeNewsWire
- 6 weeks ago - Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List - GlobeNewsWire